Kevin Judice, DiCE Molecules
Kevin Judice plays DiCE, pivoting from a $60M raise straight to the big S-1 filing
These days, it’s not hard to tell when a biotech is getting ready to launch an IPO.
Earlier this week, Kevin Judice tipped his hand …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
